

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
28 August 2008 (28.08.2008)

PCT

(10) International Publication Number  
**WO 2008/103744 A1**

(51) International Patent Classification:  
A61F 2/04 (2006.01)

(21) International Application Number:  
PCT/US2008/054440

(22) International Filing Date:  
20 February 2008 (20.02.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/902,223 20 February 2007 (20.02.2007) US

(71) Applicant (for all designated States except US): **RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY** [US/US]; Old Queens Building, Somerset and George Streets, New Brunswick, NJ 08903 (US).

(71) Applicant and

(72) Inventor: **UHRICH, Kathryn, E.** [US/US]; 1441 Evergreen Avenue, Plainfield, NJ 07060 (US).

(74) Agents: **MALEN, Peter, L.** et al.; Viksnins Harris & Padys PLLP, P.O. Box 111098, St. Paul, MN 55111-1098 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(54) Title: NERVE GUIDANCE TUBES

(57) Abstract: Provided herein are cell guidance tubes and methods for their use.



**WO 2008/103744 A1**

## NERVE GUIDANCE TUBES

5

### Statement of Government Support

This invention was made with government support under Grant # DE013207 awarded by the National Institutes of Health. The government has certain rights in the invention.

### Related Applications

10

This patent document claims the benefit of priority of U.S. Provisional Application Serial No. 60/902,223, filed February 20, 2007, which application is herein incorporated by reference.

### Background

15 Nerve damage caused by, *e.g.*, traumatic injuries to the limbs, poses an especially challenging medical problem because nerve tissue often fails to heal completely, resulting in permanent disability. There is a need for biomaterials that promote nerve regeneration.

### Summary of Certain Embodiments

20 Certain embodiments of the present invention provide a cell guidance tube that comprises an inner layer, wherein the inner layer comprises at least one biodegradable polymer, wherein the tube comprises a lumen that comprises at least one immobilized peptide mimic of a carbohydrate.

In some embodiments of the invention, the tube further comprises an outer layer, wherein the inner layer and the outer layer each comprise at least one  
25 biodegradable polymer.

Certain embodiments of the present invention provide a cell guidance tube that comprises an inner layer and an outer layer, wherein the inner layer and the outer layer each comprise at least one biodegradable polymer.

30 In some embodiments of the invention, the tube comprises a lumen that comprises a peptide mimic of a carbohydrate. In some embodiments of the invention, the carbohydrate is human natural killer cell epitope (HNK-1) or polysialic acid (PSA).

In some embodiments of the invention, the tube further comprises a middle layer disposed between the inner layer and the outer layer.

In some embodiments of the invention, the middle layer comprises at least one biodegradable polymer.

5 In some embodiments of the invention, the inner and outer layers have different degradation rates.

In some embodiments of the invention, the inner diameter of the tube is about 2-3 mm.

10 In some embodiments of the invention, the length of the tube is about 10-30 mm.

In some embodiments of the invention, the tube is formed by extrusion.

In some embodiments of the invention, at least one biodegradable polymer is a bioactive polymer.

15 In some embodiments of the invention, at least one of the inner, middle, or outer layers comprises a polymer having one or more anti-inflammatory compounds in the polymer backbone. In some embodiments of the invention, the polymer is a polyanhydride. In some embodiments of the invention, the polymer is a polyester or a polyamide.

20 In some embodiments of the invention, at least one of the inner, middle, or outer layers comprises a salicylic acid-based polymer, a salicylsalicylic acid-based polymer, or a difluorophenyl-salicylic acid-based polymer.

In some embodiments of the invention, at least one biodegradable polymer degrades to release an anti-inflammatory compound.

25 In some embodiments of the invention, at least one biodegradable polymer degrades to release salicylic acid.

In some embodiments of the invention, at least one biodegradable polymer degrades to release a non-steroidal anti-inflammatory compound.

30 In some embodiments of the invention, at least one of the inner, middle, or outer layers comprises a polymer having one or more antibiotic compounds in the polymer backbone. In some embodiments of the invention, the polymer is a

polyanhydride. In some embodiments of the invention, the polymer is a polyester or a polyamide.

In some embodiments of the invention, at least one biodegradable polymer degrades to release an antibiotic compound.

5           In some embodiments of the invention, at least one of the inner, middle, or outer layers comprises a polymer having one or more growth factor compounds in the polymer backbone. In some embodiments of the invention, the polymer is a polyanhydride. In some embodiments of the invention, the polymer is a polyester or a polyamide.

10           In some embodiments of the invention, at least one biodegradable polymer degrades to release a growth factor.

Certain embodiments of the present invention provide a method for regenerate a damaged nerve in a patient (*e.g.*, a mammal, *e.g.*, a human) in need thereof, comprising placing the cell guidance tube of the invention at a site of  
15           neuronal injury so as to regenerate the nerve. In some embodiments of the invention, the nerve is a peripheral nerve.

#### Detailed Description

Nerve damage caused by traumatic injuries to the limbs poses an especially challenging medical problem because nerve tissue often fails to heal  
20           completely, resulting in permanent disability. Studies have shown that repairing the damaged nerve with synthetic biomaterials can enhance the body's natural capacity for nerve regeneration. However, there is a need for biomaterials that maximize nerve regeneration. As described herein, polymeric materials are investigated for application to nerve repair. These polymers include:  
25           biodegradable materials designed to provide temporary structural support while the compromised nerve tissue regenerates, and at the same time reduce inflammation, pain and infection; and collagen gel matrices modified with carbohydrate peptide mimics that can promote functional recovery, *e.g.*, motor or sensory recovery.

30           Accordingly, certain embodiments provide a cell guidance tube that comprises an inner layer, wherein the inner layer comprises at least one

biodegradable polymer, wherein the tube comprises a lumen that comprises at least one immobilized peptide mimic of a growth factor.

Certain embodiments provide a cell guidance tube that comprises an inner layer and an outer layer, wherein the inner layer and the outer layer each  
5 comprise at least one biodegradable polymer.

In certain embodiments, the tube further comprises an outer layer, wherein the inner layer and the outer layer each comprise at least one biodegradable polymer.

In certain embodiments, the tube comprises a lumen that comprises a  
10 peptide mimic of a growth factor.

In certain embodiments, the growth factor is a nerve growth factor.

In certain embodiments, the growth factor is human natural killer cell epitope (HNK-1) or polysialic acid (PSA).

In certain embodiments, the tube further comprises a middle layer  
15 disposed between the inner layer and the outer layer.

In certain embodiments, the middle layer comprises at least one biodegradable polymer.

In certain embodiments, the inner and outer layers have different degradation rates.

20 In certain embodiments, the inner diameter of the tube is about 2-3 mm.

In certain embodiments, the length of the tube is about 10-30 mm.

In certain embodiments, the tube is formed by extrusion, *e.g.*, melt extrusion.

In certain embodiments, at least one biodegradable polymer is a bioactive  
25 polymer.

In certain embodiments, at least one of the inner, middle, or outer layers comprises a polymer having one or more anti-inflammatory compounds in the polymer backbone.

In certain embodiments, the polymer is a polyanhydride.

30 In certain embodiments, the polymer is a polyester or a polyamide.

In certain embodiments, at least one of the inner, middle, or outer layers comprises a salicylic acid-based polymer, a salicylsalicylic acid-based polymer, or a difluorophenyl-salicylic acid-based polymer.

5 In certain embodiments, at least one biodegradable polymer degrades to release an anti-inflammatory compound.

In certain embodiments, at least one biodegradable polymer degrades to release salicylic acid.

In certain embodiments, at least one biodegradable polymer degrades to release a non-steroidal anti-inflammatory compound.

10 In certain embodiments, at least one of the inner, middle, or outer layers comprises a polymer having one or more antibiotic compounds in the polymer backbone.

In certain embodiments, the polymer is a polyanhydride.

In certain embodiments, the polymer is a polyester or a polyamide.

15 In certain embodiments, at least one biodegradable polymer degrades to release an antibiotic compound.

In certain embodiments, at least one of the inner, middle, or outer layers comprises a polymer having one or more growth factor compounds in the polymer backbone.

20 In certain embodiments, at least one biodegradable polymer degrades to release a growth factor.

In certain embodiments, the lumen comprises collagen, chitosan, agarose or gelatin.

In certain embodiments, the lumen comprises collagen.

25 In certain embodiments, the lumen comprises longitudinal channels.

In certain embodiments, at least one of the inner, middle, or outer layers comprises a xylyl-based polymer.

In certain embodiments, at least one of the inner, middle, or outer layers comprises an iodinated salicylate-based polymer.

30 Certain embodiments provide a cell guidance tube that comprises an inner layer, wherein the inner layer comprises at least one biodegradable

polymer, wherein the tube comprises a lumen that comprises at least one immobilized peptide mimic of a carbohydrate.

Certain embodiments provide a method for regenerating a damaged nerve in a patient in need thereof, comprising placing a cell guidance tube as described  
5 herein at a site of neuronal injury so as to regenerate the nerve.

In certain embodiments, the nerve is a peripheral nerve.

Certain embodiments provide a tube as described herein for use in medical treatment or diagnosis.

Certain embodiments provide the use of a tube as described herein to  
10 prepare a medicament useful for treating a nerve injury in an animal.

An objective of this work is to develop biomaterials to aid in functional recovery from peripheral nerve injury. One objective described herein is to investigate novel biomaterials for the construction of improved bioartificial  
15 nerve grafts. The materials investigated herein include two different nerve graft components that have shown promising results in preliminary studies: 1) bioresorbable "PolymerDrugs" that release salicylic acid and/or other nonsteroidal anti-inflammatory drugs (NSAIDs) as they degrade, enabling them to serve not only as a structural scaffolding but also as a drug delivery device,  
20 and 2) immobilized peptide mimics of carbohydrates that, *e.g.*, significantly accelerate peripheral motor neuron regeneration *in vivo*. These materials are evaluated for use in the construction of nerve grafts used to reconnect the proximal and distal segments of the injured nerve. This experimental treatment has been the subject of considerable interest in recent years and is especially  
25 appropriate for completely severed nerves. Neuronal and Schwann cell growth in nerve conduits constructed from PolymerDrugs that tested favorably in initial growth and attachment studies are evaluated. The mechanical properties of the nerve conduits are characterized and further optimized to approximate the mechanical characteristics of natural nerve as closely as possible. A collagen gel-  
30 based material with covalently coupled peptide mimics, *e.g.*, of two carbohydrates known to accelerate motor neuron regeneration *in vivo*, human

natural killer cell epitope (HNK-1) and polysialic acid (PSA), are evaluated. The gel incorporating the HNK-1 and PSA glycomimetics are used to fill the lumen of the nerve graft. Nerve grafts comprising the PolymerDrug conduit filled with the glycomimetic-modified collagen gel are implanted to evaluate the *in vivo* regeneration response.

Peripheral nerves consist of parallel bundles of neuronal axons bound together by support tissue into long cables that extend from and innervate regions of the body beyond the brain and spinal cord. Damage to a peripheral nerve cable results in loss of function in the region that it innervates. Loss of sensation and motor control in the limbs can be especially debilitating. Recovery from nerve injury requires repair of the damaged nerve tissue, a challenge that has been partially met by inserting grafts of healthy nerve at the injury site. However, success rates remain less than 80%, with the prognosis dropping off as the severity of the injury increases. In an attempt to improve functional recovery, especially of more serious injuries, researchers have focused on the development of synthetic nerve grafts whose properties can be optimized to promote the healing response.

An important process for functional recovery from nerve injury is the regeneration of damaged axons across the injury site. Schwann cells, the support cells of the peripheral nervous system, aid in this process by clearing debris and producing factors that promote regeneration. A basic function that a nerve graft serves is to provide structural support at the lesion site, acting as a physical bridge across the damaged region for migrating Schwann cells and regenerating axons. In addition, synthetic nerve grafts offer the potential to deliver bioactive components to the wound site, including growth factors, anti-inflammatory drugs, and stem cells. Realizing this potential hinges on the development of new biomaterials with chemical and physical properties that meet the demanding requirements of the nerve repair environment.

A synthetic nerve graft material should: 1) interact favorably with the cellular components of nerve tissue, 2) maintain its integrity during regeneration, and 3) ideally biodegrade when regeneration is complete, leaving the biological



structure intact. A number of synthetic materials have shown some preliminary promise for nerve graft construction. However, little systematic evaluation and development of these materials has been undertaken, and none have provided the capability for drug-release. In general, synthetic nerve grafts are formed into  
5 tubular conduits and inserted into the nerve at the site of injury. The outer wall of the graft is typically a strong scaffold that can withstand suturing and tension at the site; the best results are obtained when it is filled with an inner scaffold, typically a gel-type material through which cells can grow.

A primary goal of this project is to test new materials for the inner and  
10 outer scaffolds of bioresorbable, synthetic nerve grafts. The regeneration response are evaluated in both *in vitro* and *in vivo* systems.

This technology is important and could replace donor nerve graft (autograft), such that harvesting a donor nerve is not required. This tube would provide an excellent axon regenerating environment, and we believe the  
15 PolyNSAID materials are useful because of their ability to reduce or mitigate inflammation, including neuroma formation. Furthermore, this technology allows for exploring differential cell growth patterns. For example, the exterior conduit surface can be separately modified from the interior conduit surface. Differential degradation rates may induce differential cell types to grow on the  
20 interior vs. exterior conduit surfaces. Drug release can be localized differentially to the interior vs. exterior of the conduit.

These guidance tubes could replace the need for autograft that reconnect a nerve gap in peripheral nervous system. Compared to other nerve guidance conduits, the PolyNSAID-based tubes can biodegrade into anti-inflammatory  
25 agents that can block the inflammatory cascade and provide a protective, non-scarring environment for nerve repair.

In addition to the ease of handling, some technological advantages provided herein include the ability to: locally control inflammation; control degradation rate; create multi-layer tubes; optionally laser-cut fenestrations on  
30 tube ends to assist in suturing.

This project will produce materials with properties useful for synthetic nerve graft construction, including improved strength, flexibility, and/or support for nerve regeneration. The materials may not only promote enhanced cell attachment, survival, and regeneration, but also control pain, inflammation, and  
5 infection.

The ability of nerve cells to grown on the PolyNSAID-type materials have been tested. Anti-inflammatory and biodegradable polymers (PolyAspirin® and PolyNSAID®) have been tested for neuron growth. Faster degrading polymers (*e.g.*, based upon salicylic acid and/or salsalate) and slower  
10 degrading polymers (*e.g.*, based upon diethylmalonic and/or diflunisal) were tested. Polymers (100 mg/mL) were dissolved in methylene chloride and spin-coated onto glass cover slips (18 mm diameter, 1.5 mm thickness). DRG neuron growth on polymer surfaces was tested for neuron compatibility for up to 3 days. A biodegradable polymer tube has been tested. This polymer tube (1.80 mm  
15 inner diameter and 20 mm length) was comprised of a polyanhydride polymer and was assessed by viability of DRG neurons. Notably, cell viability was maintained for up to 5 days. Spin-coated polymers and polymer tubes for neuron growth, and one conduit for nerve growth have been tested. Nerve growth patterns on mutlitple conduits comprised of polyanhydrides and poly(anhydride-  
20 esters) are being tested.

Polymers have been screened for nerve cell morphology and neurite outgrowth. Polymer degradation products (*e.g.*, NSAIDs) do not negatively influence cell growth rates. Tubes have been generated from polymers. Young's modulus (compression) was 200 MPa in dry state and about 200 MPa when  
25 hydrated. Nerves are about 0.45 MPa.

Glycopeptide mimics may be conjugated to collagen. In certain embodiments, the mimic may be an 8 amino acid peptide of HNK-1. In certain embodiments, the ubiquitous RGD may be used. In certain embodiments, the bioactivity of the mimic is retained after conjugation.

30 Suitable compounds and polymers for use in the present invention can be found, *e.g.*, in U.S. Patent No. 7,122,615, U.S. Patent No. 6,689, 350, U.S.

Patent No. 6,613,807, U.S. Patent No. 6,486,214, U.S. Patent No. 6,468,519, U.S. Application Publication Nos. 2005/0089506 and 2003/0104614, and in International Publication Number WO 2004/006863.

Cell morphology and neurite outgrowth length on polymer surfaces can be evaluated to screen for chemistries in 2D context. Cell morphology and neurite outgrowth length on collagen-coated polymer surfaces can be evaluated, as this model would mimic a 3D context. Cell morphology and neurite outgrowth length on glycomimetic collagen-coated polymer surfaces can also be evaluated, as this model would mimic a 3D, biorelevant context.

In certain embodiments of the invention, a bioactive compound may form a portion of the backbone of the polymer backbone. In certain embodiments of the invention, a bioactive compound may be comprised in a matrix formed by the polymer.


In certain embodiments of the invention, the at least 2 of the layers of the tubes have variable degradation rates and/or drug release profiles.

In certain embodiments of the invention, the tubes have about a 1.8 mm inner diameter and are about 20 mm length.


In certain embodiments of the invention, the tubes are extruded from the reaction vessel.

In certain embodiments of the invention, the polymers have unique features: bioresorbable polymers that release nonsteroidal anti-inflammatory drugs (NSAIDs) upon degradation (both structural scaffold and drug delivery system) and immobilized peptide mimics of carbohydrates that accelerate peripheral motor neuron regeneration *in vivo* (incorporate glycomimetics into lumen of tube).


In certain embodiments of the invention, a PolyNSAID used may be a salicylic acid-based polymer (adipic linker): SAA, *e.g.*,




In certain embodiments of the invention, a PolyNSAID used may be a salicylic acid-based polymer (diethylmalonic linker): SAM, *e.g.*,



5 In certain embodiments of the invention, a PolyNSAID used may be a salicylsalicylic acid-based polymer (adipic linker): SA-SA, *e.g.*,




In certain embodiments of the invention, a PolyNSAID used may be a difluorophenyl-salicylic acid-based polymer (adipic linker): DF, *e.g.*,



Certain embodiments of the invention provide easily fabricated nerve guidance tubes comprised of biodegradable polymers (*e.g.*, PolyNSAID® and/or PolyAspirin®) to enhance nerve repair. In some embodiments, the biodegradable polymers will release anti-inflammatory drugs upon polymer *in vitro* degradation.

In certain embodiments, the tube may comprise an inner layer, a middle layer, and an outer layer. The tube can be filled with, *e.g.*, glycopeptide-modified collagen. In certain embodiments, the inner layer is about 200  $\mu\text{m}$

thick. In certain embodiments, the inner layer comprises PLGA (*e.g.*, 80:20) for strength. In certain embodiments, the middle layer is about 100  $\mu\text{m}$  thick. In certain embodiments, the middle layer comprises polyDF for slow release. In certain embodiments, the outer layer is about 100  $\mu\text{m}$  thick. In certain  
5   embodiments, the outer layer comprises polySA for fast release. In certain  
embodiments, the inner lumen is about 0.6 mm, 1.0 mm, 1.5 mm, 2.5 mm, or 3.0  
mm. In certain embodiments, the length of the tube is about 3 mm. An example  
of a tube is provided below. The arrows point to the inner, middle and outer  
layers.



10

Neuronal and Schwann cell response to bioresorbable biomaterials in a  
three-dimensional, nerve conduit geometry are evaluated. Regeneration-  
enhancing peptide mimics, *e.g.*, of the carbohydrates HNK-1 mimic peptide  
(FLHTRLFV; SEQ ID NO:1), linear scramble peptide control (TVFHFRL;   
15   SEQ ID NO:2) and PSA are evaluated in collagen gels, and the neuronal and  
Schwann cell response *in vitro* are evaluated. *In vivo* testing of tubes filled with  
glycomimetic-modified collagen gels are evaluated.

#### **Biodegradable Nerve Guidance Conduits filled with Cell-inducing Matrix Filler**

20       As described herein, certain embodiments relate to (i) creating tubes from  
biodegradable polymers (in some embodiments, not bioactive polymers such as  
our PolyAspirin) (ii) filling the tubes with a matrix that will support cell growth,  
particularly nerve cells; and (iii) creating longitudinal channels within the matrix  
to enhance innervation. Filling the polymer tubes can improve mechanical  
25   stability and prevent collapse after implantation.

Previous mechanical analyses of conduits made from salicylate-based (also referred to as SAA-based) polymers have shown that the polymer composition can be brittle. As a result, xylyl-based and iodinated salicylate-based polymers were co-extruded with a polyanhydride polymer to fabricate conduits with more favorable mechanical properties. Preliminary mechanical analysis and handling demonstrated that even 10 wt% xylyl-based polymers had mechanical properties useful for a neuronal device. The melt extrusion process currently used to fabricate the conduits allows for a variety of sized hollow tubes. In addition to a protective exterior polymer sheath, an interior biological material channeled matrix will provide the necessary guidance and support for the axons of a regenerating nerve. Potential materials for the interior matrix include: collagen, chitosan, agarose, and gelatin. Initial experimentation involves short conduit segments of 3-5 mm (the length necessary for the rat and monkey model) filled with a channeled collagen matrix. Collagen is one of the main components of the extracellular matrix and has been utilized frequently for nerve regeneration applications. The fibrous nature of collagen allows for permeability and diffusion of molecules. Chitosan is also a biomaterial that has proven to promote adhesion, survival, and neurite outgrowth of nerve cells. Thus, certain embodiments provide processes and products made by the process of melt extruding biodegradable synthetic polymer into a tube and filling the tube with a channeled mechanically supportive biological matrix to promote nerve regeneration.

Current nerve guidance products on the market are hollow tube structures that serve as a protective environment for nerve regeneration but lack the necessary physical structural support for the bands of buenger (Schwann cells). As a result, a channeled matrix composed of a biological material is proposed for the interior of the polymer conduits to maximize the efficiency of axon extension and nerve regeneration.

The biocompatibility of a xylyl-based polymer conduit was compared to two controls: an uncoated glass coverslip and a PLGA (50:50) coated coverslip. PLGA is a well known biocompatible polymer often utilized for biomedical

implants. The polymers were dissolved in methylene chloride and spin-coated onto glass coverslips (18 mm diameter). Dorsal root ganglia (DRG) axonal extension was measured for a 7 day period and compared to the original DRG size. The DRGs grew as follows: on the glass surface  $827 \pm 174\%$ , on the PLGA  
5  $776 \pm 211\%$ , and on the xylyl-based polymer  $641 \pm 153\%$ .

The xylyl- polyanhydride copolymer conduit was also mechanically analyzed in compression. A five week study was conducted where samples were incubated in Dulbecco's phosphate buffered saline (DPBS) at  $37^\circ\text{C}$  and 5%  $\text{CO}_2$  for: 24 hours, 7 days, 14 days, 21 days, 28 days, and 35 days. After 35 days  
10 of incubation in DPBS, the Young's modulus decreased from  $227 \pm 29\text{ MPa}$  to  $40 \pm 16\text{ MPa}$ . As a comparison, acellular rat sciatic nerve has been reported to have a Young's modulus of  $\sim 580 \pm 150\text{ kPa}$ .

A broad, overall objective of the work presented herein is to develop  
15 advanced biomaterials to aid in functional recovery from peripheral nerve injury. An objective of the project is to investigate novel biomaterials for the construction of improved bioartificial nerve grafts. The materials selected for this study were bioresorbable polymers that have shown promising tissue interactions and bioactivity in other biomedical applications, specifically, new  
20 "PolymerDrugs" that release salicylic acid or other nonsteroidal anti-inflammatory drugs (NSAIDs) as they degrade, thus serving not only as a structural scaffolding but also as a drug delivery device. These materials are evaluated for use as nerve conduits, or guidance channels, that can be used to reconnect the proximal and distal segments of an injured nerve. This  
25 experimental treatment has been the subject of considerable interest in recent years and is especially appropriate for completely severed nerves. Another possible application would be nerve "patches", which may be useful for treatment of partially severed nerves, particularly larger diameter nerves.

Four materials were screened for their ability to support the adhesion and  
30 growth of neurons and Schwann cells, the two major cellular components involved in nerve regeneration, in a 2D environment (which mimics the nerve

patch configuration), and the mechanostuctural properties and biocompatibility were evaluated for nerve conduits formed from these materials. A novel gel matrix was evaluated as a potential interior scaffolding for the nerve conduit.

Nerve damage caused by traumatic injuries to the limbs poses an especially challenging medical problem because nerve tissue often fails to heal completely, resulting in permanent disability. Studies have shown that repairing the damaged nerve with synthetic biomaterials can enhance the body's natural capacity for nerve regeneration. However, there is a need for biomaterials that maximize nerve regeneration. In this project, polymeric materials were screened for potential application to nerve repair. These polymers are biodegradable materials designed to provide temporary structural support while the compromised nerve tissue regenerates, and at the same time promote biological repair by reducing inflammation, pain and/or infection. A new neurite growth-enhancing component of the interior scaffolding of the nerve graft was also examined.

An important process for functional recovery from nerve injury is the regeneration of damaged axons across the injury site. Schwann cells, the support cells of the peripheral nervous system, aid in this process by clearing debris and producing factors that promote regeneration. A basic function that a nerve graft serves is to provide structural support at the lesion site, acting as a physical bridge across the damaged region for migrating Schwann cells and regenerating axons. For this purpose, a synthetic nerve graft material should: 1) interact favorably with the cellular components of nerve tissue, 2) be strong and pliable, and 3) ideally biodegrade when regeneration is complete, leaving the biological structure intact. A number of synthetic materials have shown some preliminary promise for nerve graft construction. However, little systematic evaluation and development of these materials has been undertaken, and none have provided the unique capacity for timed release of anti-inflammatory drugs offered by the materials examined in the current project. These "PolymerDrugs," represent a class of novel polyanhydrides that hydrolytically degrade into salicylic acid, other nonsteroidal anti-inflammatory drugs (NSAIDs), and/or antibiotics, which



can reduce local post-operative inflammation, pain, and infection (*e.g.*, see Erdmann *et al.*, *Biomaterials* 2000, 20, 1941; Prudencio *et al.*, *Macromolecules* 2005, 38, 6895; Schmeltzer *et al.*, *Polym Bull* 2003, 49, 441; Anastasiou *et al.*, *J Polym Sci A: Polym Chem* 2003, 41, 3667; Schmeltzer *et al.*,  
5 *Biomacromolecules* 2005, 72A, 354). These polymers have been previously evaluated for controlling pain and inflammation associated with periodontal disease and deep bone infections. In addition, Uhrich *et al.* have determined that the polymers degrade via surface erosion mechanism, an aspect that is attractive for implantable drug delivery systems. The current study focused on the sub-  
10 class of salicylic acid-releasing PolymerDrugs.

Recently, molecules that aid in the correct targeting of regenerating peripheral motor axons have been identified by Dr. Schachner. Regrowth of severed peripheral motor axons to improper targets is considered a major reason for poor functional recovery. After lesions of a peripheral nerve, motor axons  
15 initially regrow at random into both the proper 'muscle' branch and the improper 'skin' branch. Two carbohydrates carried by neural cell adhesion molecules, human natural killer cell epitope HNK-1, and 2,8 polysialic acid (PSA), appear to be able to prime regenerating motor axons prior to the branch point and enable the axons to sort into their functionally appropriate tracts. Peptide mimics of  
20 these carbohydrates have been developed that similarly enhance correct targeting of the axons and recovery of motor function following a mild (2mm crush) peripheral nerve injury (Simova *et al.*, *Ann Neurol.* 2006 Oct;60(4):430-7). However the method of application is by injection of the peptides in soluble form, and does not provide for sustained delivery. It is proposed that  
25 immobilizing the peptides to a biomaterial scaffold will enhance the effect and enable the results to be extended to larger gaps.

Certain embodiments of the invention will now be illustrated by the following non-limiting Examples.

30

### Example 1

Neuronal and Schwann cell response was evaluated *in vitro* for four novel polyanhydride "PolymerDrugs" (Table 1) that hydrolytically degrade into salicylic acid or other NSAID and have been previously shown to control pain and inflammation associated with periodontal disease and deep bone infections. The polymers degrade via a surface erosion mechanism, an attractive feature for implantable drug delivery systems.

Two control surfaces were also evaluated, Poly (D,L-lactide-co-glycolide) (PLGA), a biocompatible polymer, and glass, a standard tissue culture control. Biomaterial surfaces were prepared by dissolving the polymer in methylene chloride at 100 mg/ml, spin-coating onto coverslips (18 mm diam) at 2000 rpm for 30s, evaporating the methylene chloride in a desiccator for 1 day, then sterilizing for 900 s under UV-light. For neuronal culture, surfaces were incubated with 50 µg/ml laminin for 1 hr prior to plating neurons. Dorsal root ganglia (DRG) explants were dissected from E7-8 chick embryos, placed on the polymer surfaces, and neurite outgrowth was measured at 24 hr. For Schwann cell cultures, rat Schwann cells were placed on the polymer surfaces and cell counts recorded every day for 5 days. The results indicate that neurite outgrowth was similar to the controls for SAA and somewhat reduced for the other three test polymers, though significant in all cases. Schwann cells remained viable on all four test polymers but proliferation was limited, which is desirable for controlling Schwann cell aggregation at the outer scaffold. These results indicate that all four test polymers may be suitable outer scaffolds, with SAA and Diflunisal most favorable for neurite growth.

**TABLE 1. BIOMATERIALS EVALUATED**

Type	Material	Degradation Rate
PolyAspirin	SAA	Fast
	SAM	Slow
PolyNSAID	SA-SA	Fast
	Diflunisal	Slow
Control	PLGA	—
	Glass	—

**Example 2 Neuronal and Schwann cell response to novel, bioresorbable biomaterials in a three-dimensional, nerve conduit geometry**

**Approach:** Neurite outgrowth and Schwann cell migration will be measured as a function of time in tubular nerve conduits formed from the PolymerDrugs described herein, *e.g.*, those listed in Table 1. These will be compared to those for the control polymer, PLGA. In addition, Poly (DTE carbonate), a material with minimal inflammatory potential with ability to support the adhesion and growth of neurons and Schwann cells, will be screened. Mechanical testing will also be performed on the materials.

**Plan:** Biomaterial tubes (4mm diam x 3mm long) will be prepared by solvent-casting polymers into an ice-cooled, Teflon-lined tray. Following solvent-evaporation, the flat surfaces will be rolled into tubes and the edges sealed with solvent. The tubes will be filled with a collagen gel matrix to support axonal extension and Schwann cell migration. The collagen gel will be prepared from Vitrogen 100 (Cohesion Co., Temecula, CA), a bovine type I collagen that supports nerve regeneration *in vitro* and *in vivo*. To prepare the gel, Vitrogen 100 will be neutralized with 0.1 N NaOH and diluted to 2.0 mg/ml collagen using cell

culture medium to obtain physiological pH and ionic strength. The collagen solution will be injected into the biomaterial tubes and placed in a 37°C incubator to permit gelation. In this formulation, the collagen gel represents a non-zero basal control condition that will maintain cell viability while enabling  
5 the effects of the biomaterial comprising the outer tube to be evaluated. The collagen gel may be modified to maximally enhance the regeneration response.

To evaluate axonal outgrowth, an E7 chick DRG explant will be sutured in place at the end of the tube and incubated in F12 medium (Gibco, Gaithersburg, MD) supplemented with D-glucose, L-glutamine, penicillin-  
10 streptomycin, insulin, transferrin, selenium, putrescine, progesterone, bovine pituitary extract, and nerve growth factor at 37°C and 5% CO<sub>2</sub>. Axonal growth will be measured at 24-hr intervals over a period of 5 days to determine the growth rate as a function of time. Measurements will be performed by fixing the cylinders in 4% formaldehyde (Fisher Scientific), staining with two primary  
15 antibodies, monoclonal anti-neurofilament 200 (Sigma Chemical) and monoclonal anti-neurofilament 160 (Chemicon), then counterstaining with FITC-conjugated goat anti-mouse IgG (green,  $\lambda_{exc}/\lambda_{em}=488/518$ ; Sigma Chemical) to label the neurites. The cylinder will be sliced axially and the length of growth into the tube measured as a function of radial distance from the center  
20 of the tube. In separate experiments, primary purified Schwann cells will be placed at the end of the tube by suspending them in a small amount of collagen solution and allowing it to gel on top of one end of the tube. The tubes will be placed in serum-free medium consisting of: 1:1 v/v of DMEM and Ham's F-12 medium (BioWhitaker, Walkersville, MD) supplemented with 2 mM L-  
25 glutamine, 50 U/ml of P/S, 5 µg/ml, insulin, 0.1 mM putrescine, 0.02 µM progesterone, 0.03 µM sodium selenite, and 8 µg/ml transferrin (all from Sigma Chemical, St. Louis, MO). The cultures will be incubated at 37°C in 5% CO<sub>2</sub>. A time course of migration into the tube will be measured by fixing the tubes at 24-hr intervals after seeding, staining the Schwann cell nuclei with ethidium  
30 bromide (EtBr), slicing the cylinder axially and measuring the density of nuclei as a function of axial and radial distance in the slice using confocal microscopy.

The data for the individual slices will be recombined to obtain axial and radial cell density profiles in the cylinder.

Biomaterial tubes that support neurite outgrowth and Schwann cell survival and migration will be subjected to mechanical testing. The tubes will be tested in quasistatic uniaxial tension with an Enduratec ELF 3200 in its horizontal configuration. All tests will be performed at 37°C in a humidified Plexiglas chamber. Samples will be clamped at either end with custom-designed compression grips. Alternatively, the tubes can be sutured and glued to the clamps with cyanoacrylate adhesive (Super Glue™). Samples will be stretched to failure at a constant strain rate of 0.5%/sec while continuously recording the force. Elastic modulus, ultimate tensile strength, and strain at failure will be identified from the stress-strain plots. These parameters will be compared to those previously measured for spinal nerve root and acellular sciatic nerve, which indicate that these nerves have a stiffness of ~1Mpa. The biomaterials most closely matching the mechanical properties of peripheral nerve will be further optimized by altering synthesis and processing conditions and then re-evaluated for neurite outgrowth and Schwann cell response.

### **Example 3 Immobilization of regeneration-enhancing peptide mimics in collagen gels**

**Plan:** After determining the baseline cellular responses to the conduit biomaterials, the collagen gel in the lumen of the conduit will be modified with growth factors, *e.g.*, regeneration-enhancing peptides. Bovine type I collagen works well as the gel matrix material for several reasons: it is biocompatible (fibroblast-contracted collagen gels are the structural basis for the first living tissue engineered product on the market in the United States (Apligraf, Organogenesis, Inc., Canton, MA)), supports nerve regeneration, is easily crosslinked after network formation by a variety of methods that can be used to improve its stiffness, and is amenable to grafting of peptides and molecules to modulate cell behavior. The collagen will be modified by grafting, *e.g.*, covalently grafting, molecules to it that promote neural regeneration.

The effect of two different peptides that mimic neurite growth promoting carbohydrates will be tested: a mimic of polysialic acid (PSA), and a mimic of the sulfoglucuronyl terminal residue first discovered on human natural killer cells, HNK-1. Polysialic acid has been shown to promote neurite outgrowth and synaptic plasticity; it is expressed mainly during embryonic development and is down regulated in the adult brain except for sites where active neurite outgrowth and neurogenesis occurs. The HNK-1 carbohydrate has been implicated in preferential regrowth and survival of motor axons and motor neurons in peripheral nerve regeneration, respectively. Dr. Schachner has demonstrated promising results on locomotor function with a combination of peptide mimics of these carbohydrates in soluble form via constant infusion following spinal cord injury. Individual application of the carbohydrates did not enhance functional recovery to a significant extent, although a tendency of improved recovery was observed. Peptidomimetics of the carbohydrates, which are more stable and easier to synthesize than the sugars, have proven to be at least as effective as the carbohydrates themselves in *in vitro* experiments and to be functionally more effective in a dose-response curve than the carbohydrates themselves. The peptidomimetic half-life *in vivo* is also longer than that of the carbohydrates. The mimics in solution form have been shown individually to enhance peripheral nerve regeneration in a femoral nerve injury mouse model, but regeneration ultimately fails for severe injuries spanning more than several millimeters. It is proposed herein that immobilizing these peptides to a collagen backbone will increase the residence time and availability of the mimics for regenerating axons.

To conjugate the peptide mimics, a 50mM solution of the peptide will be prepared in distilled water at 50mM, mixed with 1-ethyl-3-(3-dimethyl aminopropyl) carbodiimide (EDC) at a 5:1 molar ratio, and incubated overnight at room temperature. This will then be added to Vitrogen 100 solution, prepared as described above, with concentrations adjusted to maintain a constant final collagen concentration of 2mg/ml. The EDC activates the carboxylic group of collagen and forms an amine bond. The adhesion molecule covalently binds to collagen via nucleophilic attack of the carbon of

collagen. This technique has been used to successfully graft KRGD peptides (which contain the ubiquitous cell adhesion domain RGD), an RDG scrambled version of this peptide, and bovine serum albumin (BSA) to collagen. A maximum concentration of the grafted peptide is 12.5 $\mu$ M, and lower concentrations are achieved by mixing

5 grafted, soluble collagen with non-grafted collagen. Higher concentrations can be achieved by altering the initial peptide concentration as warranted. Our experience has shown that RGD peptides at a final concentration of 12.5  $\mu$ M significantly increase adhesion and adhesion-mediated behavior, such as cell traction, and this will represent the starting point for the peptide mimics.

10 Neurite and Schwann cell behavior will be evaluated with the gel assay. Schwann cells and sensory neurons from chick DRGs will be acquired. Motor neurons will be isolated from the ventral horns of chick embryo spinal cord according to published protocols. Axon growth and Schwann cell behavior will be evaluated as above for collagen scaffolds with combinations of grafted

15 molecules as described in Table 2. The table includes scrambled versions of the peptide mimics as controls. Each combination will be evaluated at least 4 times. Alternate concentrations/combinations will be assayed as suggested by results from the initial experimental design.

**TABLE 2. GLYCOMIMETIC CONCENTRATIONS TO BE  
EVALUATED**

<b>HNK-1 mimic</b>	<b>Scrambled HNK-1</b>	<b>PSA mimic</b>	<b>Scrambled PSA</b>
12.5 $\mu$ M		12.5 $\mu$ M	
6.25 $\mu$ M		12.5 $\mu$ M	
12.5 $\mu$ M		6.25 $\mu$ M	
	12.5 $\mu$ M	12.5 $\mu$ M	
12.5 $\mu$ M			12.5 $\mu$ M
12.5 $\mu$ M			
6.25 $\mu$ M			
	12.5 $\mu$ M		

		12.5 $\mu$ M	
		6.25 $\mu$ M	
			12.5 $\mu$ M

Axon growth will be evaluated through collagen gels with a combination of grafted HNK-1 and PSA mimics. Each row represents a different combination. Ungrafted collagen (no mimics or scrambled mimics) will serve as an additional control.

5

**Example 4 *In vivo* testing of nerve grafts constructed using PolymerDrug conduits filled with glycomimetic-modified collagen gels**

**Approach:** Nerve grafts will be assembled using the best PolymerDrugs identified in the *in vitro* studies for the outer scaffold. Optimal formulations of the HNK-1, PSA, and HNK-1 + PSA peptide mimics identified will be used for the inner scaffold. Nerve grafts will be implanted into adult mice and functional recovery evaluated at 4, 8 and 12 weeks.

**Plan:** *In vivo* testing will be performed on adult female C57BL/6J mice (Jackson Laboratory). The left femoral nerve will be exposed and transected 3 mm proximal to the bifurcation of the saphenous and quadriceps branches. The cut ends of the nerve will be inserted into the nerve graft and fixed with single epineural 11-0 nylon stitches, leaving a 2-mm gap between the proximal and distal stump. The skin wound will be closed with 6-0 sutures (Ethicon), and the animals observed for a period of 12 weeks. Three glycomimetic combinations will be tested: HNK-1 mimic only, PSA mimic only, HNK-1 + PSA mimics. In addition, three controls, scrambled HNK-1 mimic, scrambled PSA mimic, and unmodified collagen, will be performed, yielding a total of 6 conditions. Nine animals will be tested at each condition. Daily video logs of each animal will be maintained and used to analyze recovery of locomotor function as previously described, by comparing foot angle, limb extension, and step cycle to pre-injury baseline levels. At 4, 8 and 12 weeks following implantation, one-third of the animals will be sacrificed and regeneration will be analyzed at that time point. Femoral nerves will be dissected from animals, fixed by perfusion with



formaldehyde and post-fixed in 1% osmium tetroxide in 0.1M sodium cacodylate buffer, pH 7.3, for one hour at room temperature, dehydrated and embedded in resin according to standard protocols. Transverse 1- $\mu$ m thick sections from the motor and sensory nerve branches will be cut at a distance of approximately 3 mm distal to the bifurcation and stained with 1% toluidine blue/ 1% borax in distilled water. Total numbers of myelinated axons per nerve cross-section will be estimated on an Olympus microscope equipped with a motorized stage and Microsuite software using a 100x oil objective. Axonal and nerve fiber diameters will be measured in a random sample from each section. A sampling grid with a 60- $\mu$ m line spacing will be projected onto the microscope visual field. The mean orthogonal diameters of the axon (inside the myelin sheath) and of the nerve fiber (including the myelin sheath) will be measured for all myelinated axons in contact with the vertical grid lines through the sections. The mean orthogonal diameter is calculated as a mean of the line connecting the two most distal points of the profile (longest axis) and the line passing through the middle of the longest axis at a right angle. The degree of myelination will be estimated by the ratio of the axon to fiber diameter. If regeneration is successful for the 2-mm gap, as we anticipate it will be, testing will be repeated for 5- and 8-mm gaps.


#### Example 5

Mechanical analyses of conduits made from SAA-based polymers have shown that the polymer composition can be brittle. As a result, xylyl and iodinated based polymers were copolymerized with a polyanhydride polymer to fabricate conduits with more favorable mechanical properties. Preliminary mechanical analysis and handling demonstrated that the 10 w% xylyl based polymers potentially had the mechanical properties that are necessary for such a device. The melt extrusion process currently used to fabricate the conduits allows for a variety of sized hollow tubes. Current nerve guidance products on the market are hollow tube structures that serve as a protective environment for nerve regeneration but lack the necessary physical structural support for the bands of buenger (schwann cells).

As a result, a channeled matrix is proposed for the interior of the polymer conduits. There are several potential materials that could be used for the interior matrix: collagen, chitosan, agarose, and gelatin. Initial experimentation will involve short conduit segments of 3-5 mm (the length necessary for the rat and monkey model) filled with a channeled collagen matrix. Collagen is one of the main components of the extracellular matrix and has been utilized frequently for nerve regeneration applications. The fibrous nature of collagen allows for permeability and diffusion of molecules. Preliminary experiments with 3 mg/ml collagen have shown that the concentration is insufficient in holding its shape after lyophilization. Chitosan is also a biomaterial that has proven to promote adhesion, survival, and neurite outgrowth of nerve cells.

A mold will be made by placing several wires in a sheet of PDMS with tweezers and position hollow tube over the wires (see Scheme 1). The size and amount of wires can be varied. Two wire sizes are currently available: 127  $\mu\text{m}$  stainless steel [Small Parts Inc.] and 203  $\mu\text{m}$  teflon coated wires [Bioabsorbable Therapeutics]. At least ten channels will be created in the scaffolds, while an increasing number of channels may also be utilized. It is expected that there will be a particular threshold where the structural mechanical rigidity of the interior matrix will be forfeited because of too many channels.

Scheme 1



The mold will be filled with the chosen solution and then allowed to gel

around the wires. After gelling, the mold will be placed in the -80°C freezer followed by 12 hours of lyophilization at -105°C and 50 mTorr. The wires will then be extracted from the lyophilized material with tweezers and channels will remain in the matrix spanning the entire length of the conduit. The small  
5 channels may then be back-filled with another biomaterial through capillary action. The 3 mg/ml concentration will likely be an adequate filling for the channels because previous experiments have shown considerable neuron axon extension on this material. Grafted collagen, *e.g.*, HNK-1 grafted collagen, may be incorporated into the interior matrix of the conduit. Grafting of collagen has  
10 thus far been verified with fluorescence and has proven to have a grafting efficiency of ~50-60%. As a demonstration of using a growth factor, HNK-1 grafted collagen will be an appropriate filling for the channels.

**Example 6 Bioresorbable biomaterials and compatibility with neurons  
15 and Schwann cells *in vitro*.**

Materials and Methods

Neurite outgrowth, Schwann cell attachment and Schwann cell proliferation were evaluated in response to four biodegradable polyanhydrides that hydrolytically degrade into salicylic acid: (i) salicylic acid with adipic acid  
20 linker (SAA), (ii) salicylic acid with diethylmalonic acid linker (SAM), (iii) salicylsalicylic acid with adipic acid linker (SA-SA) and (iv) diflunisal (DF) with adipic acid linker. Two control surfaces were also evaluated: poly(lactic glycolic acid) (PLGA) a degradable polymer that has been used extensively as an implantable polymer, including for synthetic nerve grafts, and glass, a standard  
25 *in vitro* culture substrate for neurons and Schwann cells. These materials are summarized in Table 3.

**TABLE 3. BIOMATERIALS  
EVALUATED**

<b>Material Type</b>	<b>Polymer</b>
Biodegradable PolymerDrugs	SAA
	SAM
	SA-SA
	DF
Controls	PLGA
	Glass

**Materials and Approach.** All solvents, reagents and fine chemicals were purchased from Fisher Scientific (Pittsburg, PA) and SigmaAldrich (Milwaukee, WI) unless otherwise indicated. Cells were cultured in a 5% CO<sub>2</sub> incubator (ThermoForma, Steri-Cycle CO<sub>2</sub> incubator, Franklin, MA) and eggs were incubated in a circulated air incubator (MODEL 1550, G.Q.F. Manufacturing Co. Savannah, GA). Schwann cell and DRG were imaged on an inverted microscope (Olympus IX81, Center Valley, PA) and images were captured using a Hamamatsu digital camera system (Olympus IX81, Center Valley, PA). Neurite outgrowth and neuron morphology on each surface was observed over 3 days. Schwann cell adhesion, proliferation and cellular morphology on the same polymer surfaces were investigated over 5 days.

**Polymer Surface Preparation.** Poly (anhydride-esters) (PAE) were synthesized as previously described (Prudencio *et al.*, Macromolecules 2005, 38, 6895; Schmeltzer *et al.*, Biomacromolecules 2005, 72A, 354). These polymers (100 mg) were dissolved in 1mL of methylene chloride, then spin-coated onto glass coverslips at 2000 rpm for 30 s using a spin-coater (Headway Research, Inc., Garland, TX). Before spin-coating, glass coverslips (18 mm diameter; 0.15 mm thickness) were cleaned using Alconox (Alconox Inc., White Plains, NY)

and H<sub>2</sub>SO<sub>4</sub>:H<sub>2</sub>O<sub>2</sub> (10:1 v/v) solution and stored in 70% ethanol until use.

Coverslips were placed into 12-well plates and sterilized under UV-light at 254 nm for 900 s using a Spectrolinker XL-1500 UV crosslinker (Spectronics Corp., Westbury, NY). Polymer degradation was initiated by adding culture media to

5 each sample and incubating for 1 day at 37°C. PLGA 50:50 copolymer (Boehringer Ingelheim Inc., Germany) was used as a control polymer. Uncoated glass coverslips were also used as a control substrate.

**Neuron Isolation.** Dorsal root ganglia (DRG) were isolated from E7-8 chick embryos. Specific pathogen-free premium chick eggs were purchased from  
10 Charles River Laboratories (North Franklin, CT) and maintained in a circulated air incubator. Isolated DRGs explants were placed onto polymer-coated glass coverslips and cultured in neuronal culture medium for 3 days at 37°C in a 5% CO<sub>2</sub> incubator. Neuronal culture medium consisted of Dulbecco's Modified Eagle's Medium (DMEM)/Ham's F-12 containing 10% v/v fetal bovine serum  
15 (FBS; Atlanta Biologicals, Lawrenceville, GA), 2 mM L-glutamine, 50 U/mL penicillin/streptomycin (P/S) and 12 ng/mL nerve growth factor (Gibco, Carlsbad, CA). To improve neuron attachment, polymer-coated and control coverslips were incubated with 50 µg/mL laminin for 1 hr at 37°C prior to plating neurons. This is a standard *in vitro* protocol, since neurons fail to thrive  
20 on nearly all surfaces that have not been coated with an appropriate biological attachment factor.

**Neuronal Growth.** DRG explants on each surface were imaged on an inverted microscope at Day 1, 2, and 3. The extent of neurite outgrowth was analyzed by manually tracing the neurite outgrowth halo around the explant and  
25 calculating its mean diameter using Microsuite™ imaging software (Olympus, Soft Imaging Program, Center Valley, PA). Neurite outgrowth length was calculated as 1/2 x (mean diameter of the outgrowth halo minus mean diameter of the explant body). On Day 1, outgrowth morphology was also assessed using a score- based morphological measure. Explants that successfully attached to the  
30 surface and showed neurite outgrowth were assigned a score of 3; explants attached with slight outgrowth were scored 2; explants that attached to the

surface but showed no outgrowth were scored 1; explants that detached from the surface were scored 0.

Immunostaining was used to improve the visualization of neurons on polymer-coated surfaces. Cultures were fixed in 4% paraformaldehyde solution for 20 min at 25°C then extensively washed in immunobuffer consisting of 1% bovine serum albumin and 0.5% Triton X-100 in phosphate buffered solution (MP Biomedicals, Inc., Solon, OH). The samples were blocked with 10% goat serum in immunobuffer for 1 hr. Samples were incubated in primary antibody solution, a mixture of neurofilament 68 (1:5000) and 200 (1:1000), for 1 hr at 25°C, followed by secondary antibody incubation with anti-mouse Alexafluor 546 (1:400) (Molecular Probes, Carlsbad, CA) for 45 min at 25°C.

**Schwann Cell Preparation.** Purified primary rat Schwann cells were cultured for 5 days on the PAE-coated, PLGA-coated and uncoated glass coverslips. The Schwann cells were maintained in DMEM media with 10% FBS, glutamine and P/S. Prior to plating, cells were detached by incubating in trypsin (0.02 mg/mL) at 37°C for 5 min, and plated onto prepared surfaces at  $1 \times 10^5$  cells/well.

**Schwann cell attachment and proliferation.** Schwann cell numbers for each sample surface were evaluated by direct cell count. Nine specific locations of evenly spaced intervals for each sample were selected using the Microsuite™ program. Over a 5 day time period, cells in the nine locations on each sample were imaged daily at 10x magnification on the inverted microscope (Olympus IX 81). All experiments were repeated five times.

**Statistical Data Analysis.** Ten experimental data sets for neurite outgrowth on the polymer surfaces and five sets for Schwann cell proliferation were subjected to statistical analysis using Excel (Version 2003; Microsoft, Redmond, WA) and Statanalysis (www.DanielSoper.com). Student t-test and one-way analysis of variance (ANOVA) analysis were performed using a 95% confidence limit ( $p < 0.05$ ).

30

## Results and Discussion

**Qualitative DRG Morphology on Polymer Surfaces.** Explants on SAA and DF surfaces exhibited morphological characteristics similar to healthy explants seen on PLGA and glass coverslip controls, with significant neurite  
5 outgrowth extending from the explant perimenter. DRG's on SAM and SA-SA surfaces displayed much shorter neurites.

**Initial DRG Response.** The best response was seen for neurons on the SAA test polymer and on glass and PLGA controls, indicating attachment and extensive growth. Although the mean score for neurons on SAA was slightly  
10 lower than on the controls, the difference was not significant. Significantly lower scores were observed on SAM, SA-SA and DF surfaces.

**DRG Neuron Growth on Polymer Surfaces.** Further neuron response analysis was performed by measuring neurite outgrowth length over three days on each surface. In general, neurite length increased daily over the time period  
15 for all surfaces. Neuron growth on the four NSAID-based polymers was compared to neuron growth on a PLGA surface. Neurons on SAA surfaces showed the highest outgrowth and remained consistent with the outgrowth on the PLGA control throughout the culture time. The average outgrowth rates on SAA and 50:50 PLGA control surfaces were 583 and 553  $\mu\text{m}/\text{day}$ , respectively.  
20 Neurite length on DF-based polymer surfaces was significantly lower on Days 1 and 2 compared to the PLGA control, with no significant difference by Day 3. Neurons on SAM and SA-SA generally showed daily growth at all time points; neurite outgrowth ranges were significantly different from PLGA and uncoated glass controls. These results suggest that SAA is a neuron-compatible polymer  
25 and a potential candidate for a nerve guidance material. DF demonstrates less compatibility than SAA, but still may be sufficient with further modification (*e.g.*, coating with adhesive proteins).

**Schwann Cell Attachment and Proliferation.** The degree of Schwann cell attachment on each of the surfaces at Day 1 was evaluated. The only  
30 significant difference observed among the different surfaces was a reduced attachment to SA-SA. Cell proliferation was followed for five days. Cells on the

control surfaces demonstrated a typical proliferation pattern, with cells rapidly proliferating up to the first 3 days followed by a slower growth rate. Cell numbers were significantly lower on PLGA than on the uncoated glass control. Cell numbers on SAA and DF were nearly constant with time. Cell numbers  
5 were lowest on SA-SA and SAM surfaces, even showing a slight decrease over the culture time period. All polymers in this study, including PLGA, degrade upon contact with the media; it is possible that the degradation by-product inhibits cell proliferation to varying degrees, depending on the polymer.

**Schwann Cell Morphology.** Schwann cell morphology on the controls  
10 (50:50 PLGA and uncoated glass coverslip) showed typical Schwann cell morphology: spindle-shaped (bi-polar or tri-polar) and well flattened with oval nuclei. On SAA and DF, most cells exhibited spindle-shaped morphology, similar in appearance to the controls; however, cells tended to be more extended and lower cell numbers were observed. SAM surfaces had mixed regions of cell  
15 spreading, some cells similar in appearance to controls, and some more rounded cells that indicated lower surface compatibility. Schwann cells on SAM surfaces typically displayed a more rounded shape, and cells tended to form clusters. Cells on the SA-SA surfaces were primarily rounded.

#### 20        **Example 7 The structure, mechanical strength and biocompatibility of nerve conduits**

Of the different test polymers evaluated, the best cellular response was clearly obtained with the salicylic acid-based poly (anhydride-ester) with adipic linker (SAA). Thus, SAA was selected for further testing. Tubular conduits of  
25 SAA-based polymers were successfully fabricated with a melt extrusion method. Scanning electron microscopy was used to observe their structural integrity and compression testing was performed to quantify their mechanical properties. Although biocompatibility with neurons and Schwann cells at early times was demonstrated in Example 6, the times examined preceded the release of  
30 significant quantities of salicylic acid from the polymer. Therefore, in this aim, we also investigated the effects of released salicylic acid on Schwann cells and



neurons.

#### Materials and Methods

**Materials.** All media components, cell culture and immunostaining reagents were purchased at Sigma (St. Louis, MO), and cell flasks and well  
5 plates were purchased from Fisher Scientific (Fair Lawn, NJ), unless otherwise noted. Nerve guidance tubes were manufactured at Bioabsorbable Therapeutics (Menlo Park, CA) using a melt extrusion process.

**Scanning Electron Microscopy of Conduits.** The conduit structure was visualized using scanning electron microscopy (SEM; AMRAY 1830 I, Bedford,  
10 MA) and fluorescence microscopy (Olympus IX 81, Center Valley, PA). Conduits were cut into 3 mm lengths using a hot Accu-Knife™ (Control CO, Houston, TX) warmed with a heating gun. For fluorescence microscopy, conduits were observed at 350, 490 and 557 nm. For SEM observation, tubes were affixed to specimen mounts (Electron Microscopy Sciences, Fort  
15 Washington, PA) using nonconducting adhesive tabs (Electron Microscopy Sciences). Cross-section and surfaces of samples were gold-coated using a Sputter Coater (BALZER SCD 004; Baltec, Tuscon, AZ) and examined at an electron voltage of 20 kV.

**Compression Testing.** Mechanical analysis of polymer conduits was  
20 performed with a Perkin–Elmer DMA 7e dynamic mechanical analyzer with a TAC 7/DX thermal analysis controller (Waltham, MA). PE Pyris software (Version 3.81, Perkin Elmer, Waltham, MA) associated with the DMA was used for collecting and processing data. Conduit samples (2.7 mm x 1.8 mm i.d., n = 3) were loaded on the DMA and a perpendicular force applied to the longitudinal  
25 axis of the tubes at a 25 mN initial load ramped to 8000 mN at a rate of 200 mN/min. Temperature was maintained at 22°C and the data exported to Excel for further analysis. Young's modulus was calculated as the slope of the initial linear portion of the stress-strain curve.

**Analysis of *In vitro* Degraded Media.** To evaluate the influence of  
30 released drug on DRG neurons and Schwann cells, the polymer conduits were hydrolytically degraded in medium composed of Dulbecco's Modified Eagle's

Medium (DMEM), 10% v/v fetal bovine serum (FBS, Atlanta Biologicals, Lawrenceville, GA), 2 mM L-glutamine, and 50 U/mL penicillin/streptomycin. Three different conduits (2 cm length) were placed onto individual centrifuge tube and incubated with 3 mL of media at 37°C. Media was collected on Day 1  
5 (10% release), Day 4 (50% release), and Day 7 (100% release). Medium without released drugs was used as a control.

**DRG Neuron Isolation and Culture in Polymer Degradation Media.**

DRG neurons were removed from E7-8 chick embryos (Charles River Laboratories, North Franklin, CT) and placed in cold Hank's Buffered Salt  
10 Solution (BioWhittaker™, Combrex BioScience, Walkerville, MD). Ganglia were dissociated by incubation in 0.25% trypsin for 10 min at 37°C and triturated ten times with a fire-polished pipette.

Laminin (100 µL/well) was added to 24-well plates and incubated for 1 hr at 37°C to coat the plate surfaces. Dissociated neurons were seeded at  $5 \times 10^4$   
15 cells/well. Nerve growth factor (R&D Systems, Minneapolis, MN) was added at 12 ng/mL. Media were collected (10, 50 and 100% drug released media) and added at a volume of 500 µL per well and neurons were cultured for 24 hr in an incubator (37°C and 5% CO<sub>2</sub>; ThermoForma, Franklin, MA). All experiments were performed in triplicate.

20 **Immunostaining and Image Analysis.** After 24 hr, neurons were immunostained against neurofilament antibody. Cells were fixed with 4% paraformaldehyde for 15 min at 25°C and extensively washed in an Immunobuffer solution. Immunobuffer solution consisted of 1% bovine serum albumin and 0.5% Triton X-100. Non-specific binding was blocked by 1 hour  
25 incubation with 10% goat serum in immunobuffer. The primary antibody was prepared as the mixture of monoclonal anti-neurofilament 68 (1:5000) and 200 (1:1000) and incubated for 1 hour at 25°C. Secondary antibody, anti-mouse Alexafluor 546 (1:400; Molecular Probe, Carsbad, CA), was incubated for 45 min at 25°C. After three washes with Immunobuffer, immunostained neurons  
30 were imaged with fluorescent microscopy in red fluorescent filter range (546 nm). To investigate neuron growth, morphology and neurite outgrowth were

observed in images. Neurite outgrowth length was measured from the cell body to the neurite tip. Neurite lengths were measured and averaged (n=3) using Microsuite™ (Olympus, Soft Imaging Program, Center Valley, PA).

**Schwann Cell Isolation and Culture.** Primarily isolated Schwann cells were maintained in medium composed of DMEM, 10% FBS, 2 mM glutamine, and 50 units of penicillin and streptomycin. Confluent cells were detached from the flask by trypsin (0.25 mg/mL) incubation for 5 min at 37°C, and placed in media at  $5 \times 10^4$  cells/well. Schwann cells in degradation media (10, 50 and 100% degradation) and control medium were maintained for 3 days.

Schwann cell morphology was observed at Days 1, 2, and 3 with light-microscopy (Olympus IX 81, Center Valley, PA). To compare cell numbers between samples, multiple images were taken per sample and cell numbers were counted in each image using Microsuite™. All experiments were performed in triplicate.

**Statistical Analysis.** Neurite outgrowth and Schwann cell proliferation in degradation media were compared to cells in the control medium using a one-way analysis of variance (ANOVA; Statanalysis, www.Daniersoper.com) Significance was determined at  $p < 0.05$ .

#### Results and Discussion

**Nerve Guidance Conduit Structure.** Representative SEM images of the polymer conduits were prepared. Images at high magnification show a relatively smooth cross-section, and the inner and outer surfaces also appear generally smooth. As surface roughness has been shown to affect peripheral nerve regeneration and smoother surfaces demonstrated improved regeneration, these conduits are promising. Nerve guidance conduits were autofluorescent at 350, 490 and 557 nm the most frequently used wavelengths for biological work.

**Nerve Guidance Conduit Mechanical Strength.** Preferably, nerve conduits should maintain a fixed shape with sufficient mechanical strength to support neuron growth, glial cell attachment and proliferation. In addition, nerve conduit should maintain a stable path across the injury site to protect neuron growth, which again depends on the mechanical integrity of the conduit. Because

the nerve grafts are bridged without obvious tension into the nerve gap, compression tests are accepted to evaluate mechanical strength (Belkas *et al.*, Biomaterials. 26:1741-1749, 2005). Compression tests on the polymer conduits yielded a Young's modulus of ~200 MPa for both dry and wet form of the  
5 conduit. For comparison, a Young's modulus of tibial nerve is ~0.4 MPa. For other synthetic materials, Young's modulus values are ~660 MPa for poly(L-lactide), ~0.28 MPa for poly(glycerol sebacate) and ~260 MPa for poly(hydroxyl butylate). Although the mechanical strength of the polymer conduit is higher than natural nerve, it is closer in value than other synthetic materials.

10       **Cytocompatibility of Conduits with DRG Neurons.** To evaluate the influence of the polymer degradation products on neuron growth, conduits were incubated in the media for 1, 4, and 7 days aiming for approximately 10, 50 and 100% drug release based upon previously published data (Schmeltzer *et al.*, Biomacromolecules 2005, 72A, 354). SAA degrades into salicylic acid and  
15 adipic acid with incubation. Drug amounts were calculated at 0.2, 1.1 and 2.2 mg/mL in 10, 50 and 100% media, respectively, based on conduit weight. Neurons were cultured in the degradation media for 24 hr and media alone was used as the negative control. The incubation time was chosen because neurons attach to the surfaces and initiate neurite outgrowth within 24 hours. No  
20 significant differences were observed for neurite lengths in degradation media and control media.

**Neuron Morphology in Polymer Degradation Media.** Neuron morphology in degradation media was also observed after 24 hr. Representative images of dissociated neurons in 50% and 100% polymer degradation media and  
25 in control media were prepared. Neurons were immunostained with anti-neurofilament so that neuron bodies and neurites appear as bright circles and thin lines, respectively. The immunostained images show typical neuron morphology; neurons spread and uniformly distribute on the surfaces with extended neurites. No obvious difference between the samples and the control were observed in  
30 neuron morphology, which reinforces the cytocompatibility of polymer degradation products.

**Schwann Cell Proliferation in Polymer Degradation Media.** Schwann cells support nerve regeneration by myelinating neurons and secreting neurotrophic factors. Thus, Schwann cell response to the degradation media is an important test for potential nerve conduits. Schwann cells were cultured for 3 days in the polymer degradation media and control media. The three days of culture time is sufficient to observe cell adhesion and proliferation. Over the three days, cells revealed typical cell growth curve at all samples. The average cell numbers increased two-fold from Day 1 to Day 3, indicating at least one growth cycle. For example, cells in 100% polymer degradation media increased from 50% on Day 1 to 100% on Day 3. No significant difference ( $p < 0.05$ ) among 10, 50, and 100% degradation media and control media was observed.

**Schwann Cell Morphology in Polymer Degradation Media.** Schwann cell morphology in polymer degradation media was further observed. No notable differences in cell morphology were observed among the samples and controls. In both the degradation and control media, cells homogenously displayed typical bi-polar or tri-polar stellate morphology of Schwann cells with oval nuclei and lamellipodial extensions. Cell clustering, cell lysis, detachment from the well plates, or abnormal cellular morphology was not observed. Biocompatibility of the polymer degradation products to Schwann cells was demonstrated by the normal proliferation rate and normal morphology. Thus, the conduits are expected to positively impact Schwann cell activities.

#### **Example 8 A novel gel matrix as an interior scaffolding**

##### **Materials and Methods.**

**Collagen Scaffold Preparation.** Collagen scaffolds were prepared by neutralizing a 3mg/ml solution of type I collagen (Vitrogen, Cohesion Technologies, Temecula, CA) dissolved in 0.2N acetic acid with 0.1N NaOH (Enever *et al.*, J Surg Res, 2002. 105(2): p. 160-72). Collagen gels were diluted to 2mg/ml collagen using 10X MEM and M199 supplemented with L-glutamine and penicillin/streptomycin to obtain physiological pH and ionic strength. The collagen solution was placed in a 37°C incubator to permit self-assembly.

**Adhesion Molecule-Grafted Collagen Preparation.** HNK-1 peptide mimic-grafted collagen were prepared by replacing M199 and L-glutamine in the above recipe with the peptide of interest. Briefly, a protein/1-ethyl-3-(3-dimethyl aminopropyl) carbodiimide (EDC) solution was prepared at a 1:1 molar ratio and  
5 incubated overnight at room temperature. The EDC activates the carboxylic group of the protein and forms an amine bond. This solution was added to the normal collagen recipe described above to prepare grafted collagen, with concentrations adjusted to maintain a constant final collagen concentration of 2mg/ml. The peptide-grafted collagen self assembled into a gel upon incubation  
10 at 37°C. FITC-conjugated HNK-1 was used to verify grafting using fluorescence microscopy. Following self-assembly, the gels were rinsed for 8 days to remove any unbound fluorescence label.

**Cell Culture.** Ventral spinal cord explants from Day 8 chick embryos were cultured in HNK-1 mimic-grafted gels and control collagen gels for 4 days.  
15 Some explants were also cultured in HNK-1 mimic gradients formed using a microfluidics system.

#### Results and Discussion

**HNK-1 Grafted Collagen Gels.** The covalent coupling of HNK-1 peptide mimic to soluble collagen successfully immobilized the HNK-1 mimic to  
20 the fibrillar collagen matrix following collagen gel formation. Use of FITC conjugated mimic and extensive rinsing of the collagen gel following self assembly ensured that any fluorescence was due to HNK-1 mimic incorporated into the matrix and not to unbound mimic.


**Neurite Extension.** Data indicates that including the HNK-1 peptide  
25 within a Type I collagen gel enhances outgrowth of axons from chick embryo spinal cord explants. Neurite extension was observed for both HNK-1 mimic grafted gels and collagen control gels, but was greater for HNK-1 mimic gels. These results demonstrate that HNK-1 mimic grafted gels support neurite growth, and indicate that axon extension may be improved in biomaterials with  
30 immobilized HNK-1/HNK-1 mimics. In another experiment, when presented with a gradient of this grafted peptide via a microfluidics assay, axons from

spinal cord explants preferentially grew up the gradient of HNK-1 mimic.

### Example 9 Synthetic biodegradable polymer tubes

To overcome the potential issue of NSAID-intolerance, alternate

- 5 polymers that do not biodegrade into therapeutics were explored. For this specific aim, xylyl-based polymers were used (Anastasiou *et al.*, Macromolecules 33:6217-6221 (2000)). The xylyl based polymers were compared to PLGA (50:50) as well to the SAA-based polymer.




xylyl-based polymer

### 10 Materials and Methods

- Substrate Preparation.** Glass coverslips [18 mm] (Fisher, Phillipsburg, NJ) were prepared by spin-coating. Polymer (50 mg) was dissolved in 1 mL of methylene chloride. Polymer solution (80  $\mu$ l) was added to each glass coverslip and spun at 200 rpm for 40 seconds using a humidified spin-coater (Headway
- 15 Research, Inc., Garland, TX). Prepared glass coverslips were placed in a 12-well plate and collagen gel solution was added. Collagen gel was prepared by mixing 20  $\mu$ l of M199, 1  $\mu$ l of penicillin/streptomycin, 10  $\mu$ l of L-glutamine, and 677  $\mu$ l of 3.0 g/mL Vitrogen collagen solution (Cohesion Corp., Temecula, CA). The collagen network self-assembled into a gel when incubated at 37 °C and 5%
- 20 CO<sub>2</sub>. The experimental design of a mimetic NGC environment is shown in Scheme 2, which shows a cross-section of a tube with appropriate dimensions projected into an experimental model.

25

Scheme 2



**Cell Culture.** Dorsal root ganglia (DRG) were extracted from embryonic day 8 (E8) White Leghorn chick embryos (Charles River,

- 5 Wilmington, MA) and seeded into the three-dimensional collagen gel. DRG media consists of Dulbecco's Modified Eagle's Medium (DMEM; Sigma, St. Louis, MO), 10% v/v fetal bovine serum (Atlanta Biologicals, Lawrenceville, GA), penicillin/streptomycin, L-glutamine, and nerve growth factor.

- Neurite outgrowth was observed on day 1, 4 and 7 with a fluorescent  
10 microscope (Olympus IX81, Center Valley, PA). The circumscribed 'body' region is compared to the exterior growth area using Microsuite™ software. After 7 days of growth, the final axonal measurement was obtained by fixing the DRG with 4% formaldehyde (Fisher Scientific), staining with monoclonal anti-neurofilament 200 [1:200] (Sigma) and monoclonal anti-neurofilament 68  
15 [1:1000] (Sigma) and counterstaining with anti-mouse Alexa Fluor 546 [1:100] (Molecular Probes, Carlsbad, CA) for labeling the neurite extensions.

- Mechanical Testing.** Mechanical analysis of the polymer conduits was performed with a Bose EnduraTEC ELF 3200 (Framingham, MA). Compression testing was performed on short cylinder segments using 5 cm diameter parallel  
20 plates and a 50 lb load cell. All testing was performed at room temperature at a crosshead speed of 1.0 mm/min. The polymer conduits were compressed in the radial direction and had a length ~3 mm. Data acquisition (applied force and displacement) was performed with the WinTest software. The strain ( $\epsilon$ ) of the conduit is defined as:  $\epsilon = \frac{d_o - d}{d_o}$ , where  $d_o$  is the initial outside diameter of the  
25 tube and  $d$  is the diameter after compression.



Young's modulus values (E) were calculated using the following equation:

$$F = \frac{32\pi EI}{(\pi^2 - 8)d_o^2}(\varepsilon),$$

where I is the second moment of area defined as:  $I = \frac{\pi(r_o^4 - r_i^4)}{4}$ .

## 5 **Results and Discussion**

**Cytocompatibility.** DRGs in the NCG environment successfully adhered and showed outgrowth. When initially seeded into the collagen gel, the DRG is simply a round body with no axonal outgrowth. Polymer biocompatibility is indicated by the extent of axonal projections (the halo surrounding the dense core). A larger halo of axons typically represents a more viable environment for neuron growth. There is a general trend of an increasing axonal halo as time progresses.

Results show an overall increase of neurite outgrowth size compared to the original DRG body size for the xylyl-based polymer compared to PLGA and the uncoated glass control.

**Mechanical Properties.** A five week study was conducted where samples were incubated in Dulbecco's phosphate buffered saline (DPBS) at 37° C and 5% CO<sub>2</sub> for: 24 hours, 7 days, 14 days, 21 days, 28 days, and 35 days.

## 20 **Summary**

The biocompatibility of salicylic acid-based polymers was evaluated by culturing DRG neurons and Schwann cells on the polymer surfaces. Evaluated in terms of neuronal growth, Schwann cell adhesion and proliferation, the SAA polymer was the most promising, followed by DF. SAA demonstrated neuronal growth similar to the PLGA control, while both SAA and DF exhibited Schwann cell adhesion and proliferation rates similar to PLGA.

Tubes formed from SAA exhibit mechanostuctural properties suitable for use as nerve conduits. Degradation products released from these tubes had no adverse effect on neuronal growth, or Schwann cell adhesion and proliferation.

HNK-1 peptide mimic grafted in a 3D collagen gel matrix enhanced neurite outgrowth. The degree of grafting and the response of isolated mouse spinal cord and dorsal root ganglion neurons through gels grafted with either HNK-1 or PSA mimics will be evaluated, the dual presentation of the mimics *in vitro* will be optimizing, and then testing the optimum biomaterial *in vivo* in a mouse peripheral nerve injury model. The degradable xylyl-based polymer tubes will be filled with a mechanically supportive matrix filler (eg, collagen or chitosan) and channels appropriate for innervation will be created using 100 micron-sized rods.

10

#### LITERATURE

1. Capturing the Full Power of Biomaterials for Military Medical Needs. National Academies Press, Washington, DC, 2004.
2. Schmidt CE, Leach JB. Neural tissue engineering: strategies for repair and regeneration. *Annu Rev Biomed Eng.* 2003;5:293-347.
3. Erdmann, L; Uhrich, K. Synthesis and degradation characteristics of salicylic acid-derived poly(anhydride-esters). *Biomaterials* 2000, 20, 1941.
4. Schmeltzer, R; Uhrich, K. Synthesis and Characterization of Salicylic Acid-based Poly(anhydride-ester) Copolymers. *J Bioactive Compat Polym* accepted.
5. Prudencio, A; Schmeltzer, R; Uhrich, K. Effect of linker structure on salicylic acid-derived poly(anhydride-esters). *Macromolecules* 2005, 38, 6895.
6. Schmeltzer, R; Anastasiou, T; Uhrich, K. Optimized synthesis of salicylate-based poly(anhydride-esters). *Polym Bull* 2003, 49, 441.
7. Anastasiou, T; Uhrich, K. Aminosalicylate-based biodegradable polymers: Synthesis and *in vitro* characterization of poly(anhydride-esters) and poly(anhydride-amides). *J Polym Sci A: Polym Chem* 2003, 41, 3667.
8. Schmeltzer, R; Schmalenberg, K; Uhrich, K. Synthesis and cytotoxicity of salicylate-based poly(anhydride-esters). *Biomacromolecules* 2005, 72A, 354.
9. Schmeltzer, R; Uhrich, K. Synthesis and Hydrolytic Degradation of Antiseptic-based Poly(anhydride-esters). *Biomacromolecules* under review.
10. Erdmann, L; Macedo, B; Uhrich, K. Degradable poly(anhydride-ester) implants: Effects of localized salicylic acid release on bone. *Biomaterials* 2000, 21, 2507.
11. Harten, R; Svach, D; Schmeltzer, R; Uhrich, K. Salicylic acid-derived poly(anhydride-esters) inhibit bone formation and resorption *in vivo*. *J Biomed Mater Res: Part A* 2005, 42A, 354.
12. Whitaker-Brothers, K; Uhrich, K. Poly(anhydride-ester) fibers: Role of copolymer composition on hydrolytic degradation and mechanical properties. *J Biomed Mater Res* 2004, 70A, 309.
13. Whitaker-Brothers, K; Uhrich, K. Investigation into the Erosion Mechanism of Salicylate-based Poly(anhydride-esters). *J Biomed Mater Res: Part A* in press.
14. Tsai EC, Dalton PD, Shoichet MS, Tator CH. Synthetic hydrogel guidance channels facilitate regeneration of adult rat brainstem motor axons after complete spinal cord transection. *J Neurotrauma.* 2004 Jun;21(6):789-804.

15. Evans GR, Brandt K, Katz S, Chauvin P, Otto L, Bogle M, Wang B, Meszlenyi RK, Lu L, Mikos AG, Patrick CW Jr. Bioactive poly(L-lactic acid) conduits seeded with Schwann cells for peripheral nerve regeneration. *Biomaterials*. 2002 Feb;23(3):841-8.
- 5 16. Evans GR, Brandt K, Niederbichler AD, Chauvin P, Herrman S, Bogle M, Otta L, Wang B, Patrick CW Jr. Clinical long-term *in vivo* evaluation of poly(L-lactic acid) porous conduits for peripheral nerve regeneration. *J Biomater Sci Polym Ed*. 2000;11(8):869-78.
- 10 17. Tai HC, Buettner HM. Neurite outgrowth and growth cone morphology on micropatterned surfaces. *Biotechnol Prog*. 1998 May-Jun;14(3):364-70.
18. Thompson DM, Buettner HM. Oriented Schwann cell monolayers for directed neurite outgrowth. *Ann Biomed Eng*. 2004 Aug;32(8):1120-30.
19. Thompson DM, Buettner HM. Schwann cell response to micropatterned laminin surfaces. *Tissue Eng*. 2001 Jun;7(3):247-65.
- 15 20. Dubey, N., P.C. Letourneau, and R.T. Tranquillo, Guided neurite elongation and schwann cell invasion into magnetically aligned collagen in simulated peripheral nerve regeneration. *Exp Neurol*, 1999. 158(2): p. 338-50.
21. Ceballos, D., X. Navarro, N. Dubey, G. Wendelschafer-Crabb, W.R. Kennedy, and R.T. Tranquillo, Magnetically aligned collagen gel filling a collagen nerve
- 20 guide improves peripheral nerve regeneration. *Exp Neurol*, 1999. 158(2): p. 290-300.
22. Singh A, Lu Y, Chen C, Cavanaugh JM. Mechanical properties of spinal nerve roots subjected to tension at different strain rates. *J Biomech*. 2006;39(9):1669-76. Epub 2005 Jul 5.
- 25 23. Borschel GH, Kia KF, Kuzon WM Jr, Dennis RG. Mechanical properties of acellular peripheral nerve. *J Surg Res*. 2003 Oct;114(2):133-9.
24. Falanga, V.J., Tissue engineering in wound repair. *Adv Skin Wound Care*, 2000. 13(2 Suppl): p. 15-9.
25. Sung, H.W., W.H. Chang, C.Y. Ma, and M.H. Lee, Crosslinking of biological
- 30 tissues using genipin and/or carbodiimide. *J Biomed Mater Res*, 2003. 64A(3): p. 427-38.
26. Liang, H.C., W.H. Chang, K.J. Lin, and H.W. Sung, Genipin-crosslinked gelatin microspheres as a drug carrier for intramuscular administration: *in vitro* and *in vivo* studies. *J Biomed Mater Res*, 2003. 65A(2): p. 271-82.
- 35 27. Khor, E., Methods for the treatment of collagenous tissues for bioprotheses. *Biomaterials*, 1997. 18(2): p. 95-105.
28. Lee, C.R., A.J. Grodzinsky, and M. Spector, The effects of cross-linking of collagen-glycosaminoglycan scaffolds on compressive stiffness, chondrocyte-mediated contraction, proliferation and biosynthesis. *Biomaterials*, 2001.
- 40 22(23): p. 3145-54.
29. Girton, T.S., T.R. Oegema, E.D. Grassl, B.C. Isenberg, and R.T. Tranquillo, Mechanisms of stiffening and strengthening in media-equivalents fabricated using glycation. *J Biomech Eng*, 2000. 122(3): p. 216-23.
30. Myles, J.L., B.T. Burgess, and R.B. Dickinson, Modification of the adhesive
- 45 properties of collagen by covalent grafting with RGD peptides. *J Biomater Sci Polym Ed*, 2000. 11(1): p. 69-86.

31. Enever, P.A., D.I. Shreiber, and R.T. Tranquillo, A novel implantable collagen gel assay for fibroblast traction and proliferation during wound healing. *J Surg Res*, 2002. 105(2): p. 160-72.
- 5 32. Bromberek, B.A., P.A. Enever, D.I. Shreiber, M.D. Caldwell, and R.T. Tranquillo, Macrophages influence a competition of contact guidance and chemotaxis for fibroblast alignment in a fibrin gel coculture assay. *Exp Cell Res*, 2002. 275(2): p. 230-42.
33. Shreiber, D.I., P.A.J. Enever, and R.T. Tranquillo, Effects of PDGF-BB on rat dermal fibroblast behavior in mechanically stressed and unstressed collagen and  
10 fibrin gels. *Exp Cell Res*, 2001. 266: p. 155-166.
34. Kruse J, Mailhammer R, Wernecke H, Faissner A, Sommer I, Goridis C, Schachner M. Neural cell adhesion molecules and myelin-associated glycoprotein share a common carbohydrate moiety recognized by monoclonal antibodies L2 and HNK-1. *Nature*. 1984 Sep 13-19;311(5982):153-5.
- 15 35. Martini R, Xin Y, Schmitz B, Schachner M. The L2/HNK-1 Carbohydrate Epitope is Involved in the Preferential Outgrowth of Motor Neurons on Ventral Roots and Motor Nerves. *Eur J Neurosci*. 1992;4(7):628-639.
36. Martini R, Schachner M, Brushart TM. The L2/HNK-1 carbohydrate is preferentially expressed by previously motor axon-associated Schwann cells in  
20 reinnervated peripheral nerves. *J Neurosci*. 1994 Nov;14(11 Pt 2):7180-91.
37. Eberhardt KA, Irintchev A, Al-Majed AA, Simova O, Brushart TM, Gordon T, Schachner M. BDNF/TrkB signaling regulates HNK-1 carbohydrate expression in regenerating motor nerves and promotes functional recovery after peripheral nerve repair. *Exp Neurol*. 2006 Apr;198(2):500-10. Epub 2006 Feb 7.
- 25 38. Simova O, Irintchev A, Mehanna A, Liu J, Dihne M, Bachle D, Sewald N, Loers G, Schachner M. Carbohydrate mimics promote functional recovery after peripheral nerve repair. *Ann Neurol*. 2006 Oct;60(4):430-7.
39. Simon-Haldi M, Mantei N, Franke J, Voshol H, Schachner M. Identification of a peptide mimic of the L2/HNK-1 carbohydrate epitope. *J Neurochem*. 2002  
30 Dec;83(6):1380-8.
40. Torregrossa P, Buhl L, Bancila M, Durbec P, Schafer C, Schachner M, Rougon G. Selection of poly-alpha 2,8-sialic acid mimotopes from a random phage peptide library and analysis of their bioactivity. *J Biol Chem*. 2004 Jul 16;279(29):30707-14. Epub 2004 May 6.
- 35 41. Bachle D, Loers G, Guthohrlein EW, Schachner M, Sewald N. Glycomimetic cyclic peptides stimulate neurite outgrowth. *Angew Chem Int Ed Engl*. 2006 Oct 6;45(39):6582-5.
42. Chen J., Irintchev A., Rougon G. and Schachner M. (2006) Glycomimetics enhance locomotor recovery after spinal cord injury in adult mice. *submitted*.
- 40 43. Kuijpers, A.J., G.H. Engbers, J. Krijgsveld, S.A. Zaat, J. Dankert, and J. Feijen, Cross-linking and characterisation of gelatin matrices for biomedical applications. *J Biomater Sci Polym Ed*, 2000. 11(3): p. 225-43.
44. Gratzer, P.F. and J.M. Lee, Control of pH alters the type of cross-linking produced by 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC) treatment  
45 of acellular matrix vascular grafts. *J Biomed Mater Res*, 2001. 58(2): p. 172-9.

45. Olde Damink, L.H., P.J. Dijkstra, M.J. van Luyn, P.B. van Wachem, P. Nieuwenhuis, and J. Feijen, Cross-linking of dermal sheep collagen using a water-soluble carbodiimide. *Biomaterials*, 1996. 17(8): p. 765-73.
46. Song, M., H. Sundararaghavan, D.I. Shreiber, and K.E. Uhrich. Modifying cell adhesion to collagen gels for enhanced nerve regeneration. in BMES. 2004. Philadelphia, PA.
47. Masuko, Kuromi, and Shimada, Isolation and culture of motoneurons from embryonic chicken spinal cords, *PNAS* 76(7) 3537-3541, 1979.
48. Simova O, Irintchev A, Mehanna A, Liu J, Dihne M, Bachle D, Sewald N, Loers G, Schachner M. Carbohydrate mimics promote functional recovery after peripheral nerve repair. *Ann Neurol*. 2006 Oct;60(4):430-7.
49. Pego, A.P., Vleggeert-Lankamp, C.L., Deenen, M., Lakke, E.A., Grijpma, D.W., Poot, A.A., Marani, E. Feijen, J., Adhesion and growth of human Schwann cells on trimethylene carbonate (co)polymers. *J Biomed Mater Res A*, 2003. 67(3): p. 876-885.
50. Morrissey, T.K., Kleitman, N. Bunge, R.P., Isolation and functional characterization of Schwann cells derived from adult peripheral nerve. *J Neurosci*, 1991. 11(8): p. 2433-2442.
51. Aebischer, P., Guenard, V., Valentini, R.F., The morphology of regenerating peripheral nerves is modulated by the surface microgeometry of polymeric guidance channels, *Brain Res*. 531:211-218, 1990.
52. Belkas, J.S., Munro, C.A., Shoichet, M.S., Johnston, M., Midha, R., Long-term *in vivo* biomechanical properties and biocompatibility of poly(2-hydroxyethyl methacrylate-co-methyl methacrylate) nerve conduits, *Biomaterials*. 26:1741-1749, 2005.
53. Rydevik, B.L., Kwan, M.K., Myers, R.R., Brown, R.A., Triggs, K.J., Woo, S.L., Garfin, S.R., An *in vitro* mechanical and histological study of acute stretching on rabbit tibial nerve, *J Orthop Res*. 8:694-701, 1990.
54. Weir, N.A., Buchanan, F.J., Orr, J.F., Farrar, D.F., Boyd, A., Processing, annealing and sterilisation of poly-L-lactide, *Biomaterials*. 25:3939-3949, 2004.
55. Wang, Y., Ameer, G.A., Sheppard, B.J., Langer, R., A tough biodegradable elastomer, *Nat Biotechnol*. 20:602-606, 2002.
56. Thompson DM, Buettner HM. Oriented Schwann cell monolayers for directed neurite outgrowth. *Ann Biomed Eng*. 2004 Aug;32(8):1120-30.
57. Thompson DM, Buettner HM. Schwann cell response to micropatterned laminin surfaces. *Tissue Eng*. 2001 Jun;7(3):247-65.
58. T. Anastasiou and K. Uhrich. Novel polyanhydrides with enhanced thermal and solubility properties. *Macromolecules* 33:6217-6221 (2000).

40 All publications, patents and patent applications cited herein are incorporated herein by reference. While in the foregoing specification this invention has been described in relation to certain embodiments thereof, and many details have been set forth for purposes of illustration, it will be apparent to those skilled in the art that the invention is susceptible to additional

embodiments and that certain of the details described herein may be varied considerably without departing from the basic principles of the invention.

The use of the terms “a” and “an” and “the” and similar referents in the context of describing the invention are to be construed to cover both the singular  
5 and the plural, unless otherwise indicated herein or clearly contradicted by context. The terms “comprising,” “having,” “including,” and “containing” are to be construed as open-ended terms (*i.e.*, meaning “including, but not limited to”) unless otherwise noted. Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate  
10 value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (*e.g.*, “such  
15 as”) provided herein, is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the invention.

Embodiments of this invention are described herein, including the best  
20 mode known to the inventors for carrying out the invention. Variations of those embodiments may become apparent to those of ordinary skill in the art upon reading the foregoing description. The inventors expect skilled artisans to employ such variations as appropriate, and the inventors intend for the invention to be practiced otherwise than as specifically described herein. Accordingly, this  
25 invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by context.

30

Claims

What is claimed is:

1. A cell guidance tube that comprises an inner layer, wherein the inner layer comprises at least one biodegradable polymer, wherein the tube comprises a lumen that comprises at least one immobilized peptide mimic of a growth factor.
2. The tube of claim 1 that further comprises an outer layer, wherein the inner layer and the outer layer each comprise at least one biodegradable polymer.
3. A cell guidance tube that comprises an inner layer and an outer layer, wherein the inner layer and the outer layer each comprise at least one biodegradable polymer.
4. The tube of claim 3, wherein the tube comprises a lumen that comprises a peptide mimic of a growth factor.
5. The tube of any one of claims 1, 2 or 4, wherein the growth factor is a nerve growth factor.
6. The tube of any one of claims 1, 2, 4 or 5, wherein the growth factor is human natural killer cell epitope (HNK-1) or polysialic acid (PSA).
7. The tube of any one of claims 2-6 that further comprises a middle layer disposed between the inner layer and the outer layer.
8. The tube of claim 7, wherein the middle layer comprises at least one biodegradable polymer.

9. The tube of any one of claims 2-8, wherein the inner and outer layers have different degradation rates.
10. The tube of any one of claims 1-9, wherein the inner diameter of the tube is about 2-3 mm.
11. The tube of any one of claims 1-10, wherein the length of the tube is about 10-30 mm.
12. The tube of any one of claims 1-11, wherein the tube is formed by extrusion.
13. The tube of any one of claims 1-12, wherein at least one biodegradable polymer is a bioactive polymer.
14. The tube of any one of claims 1-13, wherein at least one of the inner, middle, or outer layers comprises a polymer having one or more anti-inflammatory compounds in the polymer backbone.
15. The tube of claim 14, wherein the polymer is a polyanhydride.
16. The tube of claim 14, wherein the polymer is a polyester or a polyamide.
17. The tube of any one of claims 1-13, wherein at least one of the inner, middle, or outer layers comprises a salicylic acid-based polymer, a salicylsalicylic acid-based polymer, or a difluorophenyl-salicylic acid-based polymer.
18. The tube of any one of claims 1-13, wherein at least one biodegradable polymer degrades to release an anti-inflammatory compound.



19. The tube of any one of claims 1-13, wherein at least one biodegradable polymer degrades to release salicylic acid.
20. The tube of any one of claims 1-13, wherein at least one biodegradable polymer degrades to release a non-steroidal anti-inflammatory compound.
21. The tube of any one of claims 1-20, wherein at least one of the inner, middle, or outer layers comprises a polymer having one or more antibiotic compounds in the polymer backbone.
22. The tube of claim 21, wherein the polymer is a polyanhydride.
23. The tube of claim 21, wherein the polymer is a polyester or a polyamide.
24. The tube of any one of claims 1-23, wherein at least one biodegradable polymer degrades to release an antibiotic compound.
25. The tube of any one of claims 1-24, wherein at least one of the inner, middle, or outer layers comprises a polymer having one or more growth factor compounds in the polymer backbone.
26. The tube of claim 25, wherein the polymer is a polyanhydride.
27. The tube of claim 25, wherein the polymer is a polyester or a polyamide.
28. The tube of any one of claims 1-27, wherein at least one biodegradable polymer degrades to release a growth factor.
29. The tube of any one of claims 1, 2 or 4-28, wherein the lumen comprises collagen, chitosan, agarose or gelatin.

30. The tube of claim 29, wherein the lumen comprises collagen.
31. The tube of any one of claims 1, 2 or 4-30, wherein the lumen comprises longitudinal channels.
32. The tube of any one of claims 1-31, wherein at least one of the inner, middle, or outer layers comprises a xylyl-based polymer.
33. The tube of any one of claims 1-32, wherein at least one of the inner, middle, or outer layers comprises an iodinated salicylate-based polymer.
34. A cell guidance tube that comprises an inner layer, wherein the inner layer comprises at least one biodegradable polymer, wherein the tube comprises a lumen that comprises at least one immobilized peptide mimic of a carbohydrate.
35. A method for regenerating a damaged nerve in a patient in need thereof, comprising placing the cell guidance tube of any one of claims 1-34 at a site of neuronal injury so as to regenerate the nerve.
36. The method of claim 35, wherein the nerve is a peripheral nerve.
37. A tube as described by any one of claims 1-34 for use in medical treatment or diagnosis.
38. The use of a tube as described in any one of claims 1-34 to prepare a medicament useful for treating a nerve injury in an animal.

## INTERNATIONAL SEARCH REPORT

International application No.  
**PCT/US2008/054440****A. CLASSIFICATION OF SUBJECT MATTER****A61F 2/04(2006.01)i**

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC 8 A61F 2/04, A61B 17/00

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

eKIPASS, NCBI PubMed database, Delphion Research Intellectual Property Network database

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5,030,225 A (Aebischer et al.) Jul. 9, 1991 See the column 7, lines 18-26, See the column 5, lines 56-58.	1-13, 17, 19, 25-34, 37-38
Y	US 5,834,029 A (Bellamkonda et al.) Nov. 10, 1998 See the claim 1.	1-13, 17, 19, 25-34, 37-38
Y	US 4,963,146 A (Li) Oct. 16, 1990 See the column 7, lines 55-59.	7-8, 12
Y	Makoto Yanagisawa et al. Glycobiology, Vol.17(7) ; 57-74 (Feb. 16, 2007) See the pages 60-61.	6
Y	US 5,011,486 A (Aebischer et al.) Apr. 30, 1991 See the column 5, lines 5-7.	25-28



Further documents are listed in the continuation of Box C.



See patent family annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&amp;" document member of the same patent family

Date of the actual completion of the international search

30 JULY 2008 (30.07.2008)

Date of mailing of the international search report

**30 JULY 2008 (30.07.2008)**

Name and mailing address of the ISA/KR

Korean Intellectual Property Office  
Government Complex-Daejeon, 139 Seonsa-ro, Seo-  
gu, Daejeon 302-701, Republic of Korea

Facsimile No. 82-42-472-7140

Authorized officer

JEONG Eui Jun

Telephone No. 82-42-481-5549



**INTERNATIONAL SEARCH REPORT**

International application No.

**PCT/US2008/054440****Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 35 and 36  
because they relate to subject matter not required to be searched by this Authority, namely:  
Claims 35 and 36 pertain to methods for treatment of the human or animal body by therapy methods, and thus relate to a subject matter which this International Searching Authority is not required, under Article 17(2)(a)(i) of the PCT and Rule 39(iv) of the Regulations under the PCT, to search.
2. ☒ Claims Nos.: 14-16, 18, 20-24  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:  
Claims 14-16, 18 and 20-24 are not supported by the description as required by PCT Article 6, as their scope is broader than justified by the description.
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

**Remark on Protest**

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International application No.

**PCT/US2008/054440**

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5030225 A	09.07.1991	-NONE-	
US 5834029 A	10.11.1998	AT 255425 E AU 1995-31423 A1 CA 2194493 AA DE 69532240 C0 EP 0772466 B1 EP 0772466 A1 FI 970218 A IL 114672 A0 JP 10-503098 T2 KR 10-1997-0704481 NO 970155 A TR 960078 A2 US 6156572 A WO 96-02286 A1 ZA 9506033 A	15.12.2003 16.02.1996 01.02.1996 15.01.2004 03.12.2003 14.05.1997 17.03.1997 27.11.1995 24.03.1998 06.09.1997 19.03.1997 21.06.1996 05.12.2000 01.02.1996 11.03.1996
US 4963146 A	16.10.1990	US 5026381 A	25.06.1991
US 5011486 A	30.04.1991	AU 1989-46205 A1 CA 1328710 A1 WO 90-05552 A1	12.06.1990 26.04.1994 31.05.1990